High_JJ Prevalence_NN of_IN Human_NP Papillomavirus_NP (_( HPV_NP )_) Infections_NP and_CC High_NP Frequency_NP of_IN Multiple_NP HPV_NP Genotypes_NP in_IN Human_NP Immunodeficiency_NN Virus-Infected_NP Women_NP in_IN Brazil_NP A_DT group_NN of_IN 208_CD human_JJ immunodeficiency_NN virus_NN (HIV)-infected_VBD women_NNS in_IN Brazil_NP were_VBD studied_VBN for_IN the_DT presence_NN of_IN human_JJ papillomavirus_NN with_IN the_DT general_JJ SPF10_NP PCR_NP primer_NN set_VBD ._SENT Virtually_RB all_RB (_( 98_CD %_NN )_) women_NNS were_VBD found_VBN positive_JJ for_IN human_JJ papillomavirus_NNS (_( HPV_NP )_) DNA_NP ._SENT Genotyping_NN by_IN the_DT reverse_JJ hybridization_NN line_NN probe_NN assay_NN (_( HPV-LiPA_NP )_) revealed_VBD a_DT high_JJ prevalence_NN of_IN multiple_JJ genotypes_NNS (_( 78.9_CD %_NN of_IN the_DT cases_NNS )_) ,_, with_IN an_DT average_NN of_IN 3.1_CD genotypes_NNS per_IN patient_NN (_( range_NN ,_, 1_CD to_TO 10_CD genotypes_NNS )_) ._SENT HPV_NP 6_CD was_VBD the_DT most_RBS prevalent_JJ genotype_NN and_CC was_VBD observed_VBN in_IN 80_CD (_( 39.2_CD %_NN )_) patients_NNS ,_, followed_VBN by_IN types_NNS 51_CD (_( 31.9_CD %_NN )_) ,_, 11_CD (_( 26.0_CD %_NN )_) ,_, 18_CD (_( 24.0_CD %_NN )_) ,_, and_CC 16_CD (_( 22.5_CD %_NN )_) ._SENT Of_IN the_DT genotypes_NNS detected_VBD ,_, 40.9_CD %_NN were_VBD low-risk_JJ genotypes_NNS ._SENT Twenty-two_NP (_( 10.5_CD %_NN )_) patients_NNS showed_VBD normal_JJ (_( Pap_NN I_CD )_) cytology_NN ,_, 149_CD (_( 71.6_CD %_NN )_) patients_NNS had_VBD inflammation_NN (_( Pap_NP II_NP )_) ,_, and_CC 28_CD patients_NNS (_( 13.4_CD %_NN )_) had_VBD a_DT Pap_JJ III_NP score_NN ._SENT The_DT prevalence_NN of_IN high-risk_JJ genotypes_NNS increased_VBN with_IN the_DT cytological_JJ classification_NN ._SENT There_EX were_VBD no_DT significant_JJ associations_NNS between_IN the_DT number_NN of_IN HPV_NP genotypes_NNS detected_VBD and_CC the_DT cytological_JJ classification_NN ,_, HIV_NP viral_JJ load_NN ,_, and_CC CD4_NP count_NN in_IN these_DT patients_NNS ._SENT In_IN conclusion_NN ,_, the_DT highly_RB sensitive_JJ SPF10_NP LiPA_NP system_NN shows_VBZ that_IN a_DT very_RB high_JJ proportion_NN of_IN HIV-infected_JJ women_NNS in_IN Brazil_NP are_VBP infected_VBN with_IN HPV_NP and_CC often_RB carry_VB multiple_JJ HPV_NP genotypes_NNS ._SENT Human_NP papillomavirus_NP (_( HPV_NP )_) infections_NNS are_VBP associated_VBN with_IN benign_JJ and_CC malignant_JJ lesions_NNS of_IN cutaneous_JJ and_CC mucosal_JJ epithelia_NN ._SENT So_RB far_RB ,_, more_JJR than_IN 100_CD different_JJ HPV_NP genotypes_NNS have_VBP been_VBN identified_VBN ,_, of_IN which_WDT more_JJR than_IN 40_CD have_VBP been_VBN detected_VBN in_IN the_DT anogenital_JJ area_NN ._SENT Diagnosis_NN of_IN HPV_NP infection_NN is_VBZ almost_RB entirely_RB based_VBN on_IN molecular_JJ tools_NNS ,_, which_WDT are_VBP mainly_RB PCR-based_JJ ._SENT General_NP or_CC consensus_NN PCR_NP primers_NNS have_VBP been_VBN developed_VBN that_WDT detect_VBP a_DT broad_JJ spectrum_NN of_IN HPV_NP genotypes_NNS in_IN a_DT single_JJ PCR_NP ._SENT HPV_NP genotypes_NNS that_WDT have_VBP been_VBN detected_VBN in_IN cervical_JJ carcinomas_NNS and_CC in_IN precursor_NN lesions_NNS ,_, e.g._FW ,_, HPV_NP 16_CD and_CC 18_CD ,_, are_VBP defined_VBN as_IN high-risk_JJ genotypes_NNS and_CC imply_VB a_DT comparatively_RB high_JJ risk_NN for_IN invasive_JJ disease_NN ._SENT In_IN contrast_NN ,_, other_JJ genotypes_NNS (_( e.g._FW ,_, HPV_NP 6_CD and_CC 11_CD )_) are_VBP considered_VBN low-risk_JJ genotypes_NNS because_IN they_PP are_VBP associated_VBN with_IN a_DT relatively_RB low_JJ risk_NN for_IN the_DT development_NN of_IN cervical_JJ carcinoma_NN ._SENT Only_RB a_DT small_JJ proportion_NN of_IN HPV-infected_JJ women_NNS will_MD eventually_RB develop_VB cervical_JJ neoplasia_NN ,_, and_CC the_DT precise_JJ etiologic_JJ role_NN of_IN HPV_NP and_CC natural_JJ history_NN of_IN the_DT infection_NN remain_VBP unknown_JJ ._SENT The_DT status_NN of_IN the_DT immune_JJ system_NN is_VBZ considered_VBN a_DT crucial_JJ factor_NN in_IN HPV_NP infections_NNS and_CC may_MD determine_VB the_DT development_NN of_IN persistence_NN after_IN primary_JJ infection_NN ,_, which_WDT has_VBZ emerged_VBN in_IN several_JJ studies_NNS as_IN an_DT important_JJ risk_NN factor_NN for_IN cervical_JJ neoplasia_NN ._SENT HPV-associated_JJ malignancies_NNS occur_VBP at_IN increased_VBN rates_NNS in_IN human_JJ immunodeficiency_NN virus_NN (HIV)-infected_JJ persons_NNS ,_, and_CC HPV_NP DNA_NP is_VBZ commonly_RB detected_VBN in_IN the_DT genital_JJ mucosa_NN of_IN HIV-infected_JJ women_NNS ._SENT The_DT prevalence_NN of_IN infection_NN is_VBZ generally_RB much_RB higher_JJR than_IN in_IN control_NN groups_NNS comprising_VBG seronegative_JJ women_NNS of_IN similar_JJ sociodemographic_JJ characteristics_NNS ._SENT This_DT may_MD be_VB explained_VBN by_IN an_DT HIV-impaired_JJ immune_JJ system_NN ,_, which_WDT permits_VBZ a_DT high_JJ HPV_NP viral_JJ load_NN and_CC persistent_JJ HPV_NP infection_NN ,_, leading_VBG to_TO an_DT increased_VBN risk_NN for_IN the_DT development_NN of_IN cervical_JJ neoplasia_NN ._SENT In_IN addition_NN ,_, individuals_NNS practicing_VBG unprotected_JJ sexual_JJ activities_NNS have_VBP a_DT combined_JJ risk_NN of_IN being_VBG infected_VBN by_IN HIV_NP and_CC HPV_NP because_IN these_DT viruses_NNS may_MD have_VB a_DT common_JJ mode_NN of_IN acquisition_NN ._SENT The_DT aim_NN of_IN the_DT present_JJ study_NN was_VBD to_TO assess_VB the_DT prevalence_NN of_IN HPV_NP infections_NNS in_IN a_DT group_NN of_IN HIV-infected_JJ women_NNS and_CC to_TO investigate_VB the_DT presence_NN of_IN specific_JJ HPV_NP genotypes_NNS with_IN the_DT highly_RB sensitive_JJ and_CC specific_JJ SPF10_NP HPV_NP DNA_NP detection_NN and_CC genotyping_NN method_NN ._SENT Patients_NNS ._SENT |_SYM HIV-infected_JJ women_NNS attending_VBG two_CD specialized_JJ centers_NNS in_IN Sao_NP Paulo_NP ,_, Brazil_NP (_( Instituto_NP de_NP Infectologia_NP Emilio_NP Ribas_NP and_CC Casa_NP da_NP AIDS_NP )_) ,_, for_IN a_DT routine_JJ visit_NN to_TO the_DT gynecologist_NN between_IN December_NP 1997_CD and_CC September_NP 1999_CD were_VBD invited_VBN to_TO participate_VB in_IN the_DT study_NN ._SENT All_DT patients_NNS provided_VBD informed_JJ consent_NN ._SENT Patients_NNS with_IN a_DT CD4_NP cell_NN count_NN of_IN less_JJR than_IN 50_CD per_IN mul_NN were_VBD excluded_VBN from_IN the_DT study_NN ._SENT Enrolled_VBN patients_NNS (_( n_NN =_SYM 208_CD )_) underwent_VBD a_DT gynecological_JJ evaluation_NN ,_, and_CC cervical_JJ scrape_NN samples_NNS were_VBD collected_VBN for_IN cytological_JJ analysis_NN and_CC HPV_NP DNA_NP PCR_NP ._SENT A_DT blood_NN sample_NN was_VBD obtained_VBN to_TO determine_VB the_DT HIV_NP viral_JJ load_NN ._SENT A_DT CD4_NP cell_NN count_NN was_VBD accepted_VBN for_IN the_DT study_NN purpose_NN if_IN it_PP had_VBD been_VBN performed_VBN within_IN 3_CD months_NNS of_IN the_DT visit_NN date_NN ._SENT Otherwise_RB ,_, a_DT blood_NN sample_NN for_IN CD4_NP determination_NN was_VBD also_RB obtained_VBN at_IN the_DT visit_NN date_NN ._SENT One_CD hundred_CD and_CC sixty-four_NN patients_NNS (_( 79_CD %_NN )_) were_VBD using_VBG antiretroviral_JJ agents_NNS (_( mainly_RB a_DT combination_NN of_IN two_CD nucleoside_NN analogue_NN reverse_JJ transcriptase_NN inhibitors_NNS and_CC one_CD protease_NN inhibitor_NN )_) ._SENT This_DT study_NN was_VBD approved_VBN by_IN the_DT ethical_JJ committees_NNS of_IN the_DT participating_VBG institutions_NNS ._SENT Cytology_NN and_CC histology_NN ._SENT |_SYM Pap_NN smears_NNS were_VBD examined_VBN and_CC classified_VBN according_VBG to_TO the_DT Pap_NN classification_NN ,_, comprising_VBG Pap_NN I_PP (_( normal_JJ )_) ,_, Pap_NP II_NP (_( inflammation_NN )_) ,_, Pap_NP III_NP (_( dysplasia_NN )_) ,_, Pap_NP IV_NP (_( carcinoma_NN in_IN situ_NN )_) ,_, and_CC Pap_NN V_NN (_( carcinoma_NN )_) ._SENT All_DT patients_NNS showing_VBG cytologically_RB abnormal_JJ smears_NNS (_( higher_JJR than_IN class_NN II_NP )_) were_VBD referred_VBN for_IN colposcopy-directed_NN biopsy_NN ._SENT Cervical_JJ biopsy_NN specimens_NNS were_VBD histologically_RB examined_VBN and_CC classified_VBN according_VBG to_TO the_DT cervical_JJ intraepithelial_JJ neoplasia_NN (_( CIN_NP )_) system_NN ._SENT DNA_NP isolation_NN ._SENT |_SYM Cervical_JJ samples_NNS were_VBD collected_VBN with_IN the_DT brush_NN provided_VBN in_IN Digene_NP 's_POS Hybrid_NP Capture_NP II_NP kit_NN (_( Digene_NP Corp._NP ,_, Gaithersburg_NP ,_, Md._NP )_) and_CC transported_VBN to_TO the_DT lab_NN within_IN 48_CD h_NN in_IN the_DT sample_NN transport_NN medium_NN ._SENT In_IN the_DT lab_NN ,_, denaturation_NN was_VBD performed_VBN upon_IN arrival_NN ,_, according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._SENT Four_CD hundred_CD and_CC fifty_CD microliters_NNS were_VBD removed_VBN ,_, and_CC DNA_NP was_VBD precipitated_VBN by_IN addition_NN of_IN 45_CD mul_NN of_IN 3_CD M_NP sodium_NN acetate_NN and_CC 900_CD mul_NN of_IN 100_CD %_NN ethanol_NN ._SENT Precipitated_VBN DNA_NN was_VBD washed_VBN ,_, dried_VBD ,_, and_CC resuspended_VBD in_IN 100_CD mul_NN of_IN 0.1_CD M_NP Tris-1_NP mM_NP EDTA_NP (_( pH_NN 8.3_CD )_) ,_, and_CC 10_CD mul_NN was_VBD used_VBN for_IN PCR_NP ._SENT A_DT cervical_JJ smear_NN was_VBD always_RB performed_VBN before_IN the_DT collection_NN of_IN cells_NNS in_IN hybrid_JJ capture_NN sample_NN transport_NN medium_NN ._SENT HPV_NP DNA_NP amplification_NN and_CC detection_NN ._SENT |_SYM HPV_NP DNA_NP was_VBD amplified_VBN by_IN the_DT SPF10_NP PCR_NP primer_NN set_NN ,_, and_CC each_DT run_NN was_VBD accompanied_VBN by_IN several_JJ quality_NN control_NN samples_NNS ._SENT During_IN each_DT PCR_NP run_NN ,_, 18_CD samples_NNS were_VBD tested_VBN ,_, together_RB with_IN 1_CD negative_JJ control_NN (_( water_NN )_) and_CC 1_CD positive_JJ control_NN (_( HPV_NP 18-containing_NP cells_NNS )_) ._SENT Amplification_NN products_NNS were_VBD first_RB tested_VBN by_IN probe_NN hybridization_NN in_IN a_DT microtiter_NN plate_NN assay_NN to_TO detect_VB the_DT presence_NN of_IN HPV_NP DNA_NP as_RB described_VBD earlier_RBR ,_, and_CC this_DT assay_NN also_RB included_VBD appropriate_JJ negative_JJ and_CC positive_JJ controls_NNS ._SENT SFP10-amplimers_NNS from_IN HPV-positive_JJ samples_NNS were_VBD subsequently_RB analyzed_VBN by_IN reverse_JJ hybridization_NN on_IN the_DT HPV_NP reverse_NN hybridization_NN line_NN probe_NN assay_NN (_( LiPA_NP )_) ._SENT This_DT assay_NN comprises_VBZ a_DT membrane_NN strip_NN containing_VBG type-specific_JJ oligonucleotide_NN probes_NNS ,_, immobilized_VBN as_IN parallel_JJ lines_NNS ._SENT PCR_NP products_NNS are_VBP hybridized_VBN at_IN high_JJ stringency_NN to_TO these_DT probes_NNS ,_, generating_VBG a_DT type-specific_JJ hybridization_NN pattern_NN ._SENT The_DT HPV-LiPA_NP permits_VBZ specific_JJ detection_NN of_IN 25_CD HPV_NP genotypes_NNS ,_, HPV_NP 6_CD ,_, 11_CD ,_, 16_CD ,_, 18_CD ,_, 31_CD ,_, 33_CD ,_, 34_CD ,_, 35_CD ,_, 39_CD ,_, 40_CD ,_, 42_CD ,_, 43_CD ,_, 44_CD ,_, 45_CD ,_, 51_CD ,_, 52_CD ,_, 53_CD ,_, 54_CD ,_, 56_CD ,_, 58_CD ,_, 59_CD ,_, 66_CD ,_, 68/73_CD ,_, 70_CD ,_, and_CC 74_CD ._SENT HPV_NP 6_CD ,_, 11_CD ,_, 34_CD ,_, 40_CD ,_, 42_CD ,_, 43_CD ,_, 44_CD ,_, 53_CD ,_, 54_CD ,_, 70_CD ,_, and_CC 74_CD were_VBD considered_VBN low-risk_JJ types_NNS ,_, whereas_IN HPV_NP 16_CD ,_, 18_CD ,_, 31_CD ,_, 33_CD ,_, 35_CD ,_, 39_CD ,_, 45_CD ,_, 51_CD ,_, 52_CD ,_, 56_CD ,_, 58_CD ,_, 59_CD ,_, 66_CD ,_, and_CC 68_CD were_VBD considered_VBN high-risk_JJ types_NNS ._SENT Part_NN of_IN the_DT beta-globin_NN gene_NN was_VBD amplified_VBN from_IN each_DT sample_NN as_IN a_DT positive_JJ control_NN for_IN DNA_NN isolation_NN ._SENT Appropriate_JJ negative_JJ and_CC positive_JJ controls_NNS were_VBD used_VBN to_TO monitor_VB the_DT performance_NN of_IN the_DT method_NN ._SENT HIV_NP viral_JJ load_NN ._SENT |_SYM Blood_NP was_VBD drawn_VBN by_IN venipuncture_NN and_CC centrifuged_VBN within_IN 6_CD h._NP Plasma_NP was_VBD separated_VBN and_CC frozen_VBN until_IN processed_VBN for_IN viral_JJ load_NN ._SENT The_DT HIV_NP Monitor_NP version_NN 1.0_CD assay_NN (_( Roche_NP Molecular_NP Systems_NP ,_, Sao_NP Paulo_NP ,_, Brazil_NP )_) was_VBD employed_VBN for_IN viral_JJ load_NN determination_NN on_IN all_DT samples_NNS ,_, presenting_VBG a_DT linear_JJ detection_NN range_NN of_IN 400_CD to_TO 750,000_CD copies/ml_NN ._SENT Statistical_JJ analyses_NNS ._SENT |_SYM Data_NP were_VBD analyzed_VBN with_IN the_DT chi-square_NN test_NN ,_, with_IN a_DT value_NN of_IN 0.05_CD considered_VBD the_DT threshold_NN level_NN for_IN significance_NN ._SENT A_DT total_NN of_IN 208_CD patients_NNS were_VBD enrolled_VBN in_IN the_DT study_NN ._SENT The_DT mean_JJ age_NN of_IN the_DT patients_NNS was_VBD 32.1_CD years_NNS (_( range_NN ,_, 18_CD to_TO 67_CD years_NNS )_) ._SENT HPV_NP DNA_NP was_VBD detected_VBN in_IN 204_CD (_( 98_CD %_NN )_) of_IN the_DT 208_CD patients_NNS by_IN SPF10_NP PCR_NP ._SENT All_DT negative_JJ controls_NNS and_CC positive_JJ controls_NNS for_IN PCR_NP amplification_NN ,_, HPV_NP DNA_NP detection_NN ,_, and_CC genotyping_NN yielded_VBD the_DT appropriate_JJ results_NNS ._SENT The_DT HPV_NP DNA-positive_NP samples_NNS were_VBD further_RBR analyzed_VBN by_IN genotyping_NN on_IN the_DT HPV-LiPA_NP ,_, and_CC results_NNS are_VBP shown_VBN in_IN Fig._NN ._SENT From_IN 100_CD of_IN the_DT patients_NNS ,_, the_DT SFP10_NP PCR_NP products_NNS were_VBD analyzed_VBN on_IN two_CD independent_JJ LiPA_NP strips_NNS ,_, and_CC these_DT duplicates_NNS yielded_VBD the_DT same_JJ typing_VBG results_NNS in_IN all_DT cases_NNS ._SENT In_IN two_CD (_( 0.9_CD %_NN )_) patients_NNS ,_, HPV_NP DNA_NP was_VBD detected_VBN ,_, but_CC the_DT HPV-LiPA_NP did_VBD not_RB reveal_VB a_DT genotype_NN ._SENT Thus_RB ,_, HPV_NP genotypes_NNS were_VBD available_JJ from_IN 202_CD patients_NNS ._SENT HPV_NP 6_CD was_VBD the_DT most_RBS prevalent_JJ genotype_NN and_CC was_VBD observed_VBN in_IN 80_CD (_( 39.2_CD %_NN )_) patients_NNS ,_, followed_VBN by_IN types_NNS 51_CD (_( 31.9_CD %_NN )_) ,_, 11_CD (_( 26.0_CD %_NN )_) ,_, 18_CD (_( 24.0_CD %_NN )_) ,_, and_CC 16_CD (_( 22.5_CD %_NN )_) ._SENT Overall_RB ,_, single_JJ genotypes_NNS were_VBD found_VBN in_IN 43_CD (_( 21.1_CD %_NN )_) and_CC multiple_JJ genotypes_NNS were_VBD detected_VBN in_IN 161_CD (_( 78.9_CD %_NN )_) of_IN the_DT 204_CD HPV_NP DNA-positive_NP patients_NNS ._SENT In_IN the_DT HPV_NP DNA-positive_NP patients_NNS ,_, an_DT average_NN of_IN 3.1_CD types_NNS per_IN patient_NN were_VBD detected_VBN ,_, ranging_VBG from_IN 1_CD to_TO 10_CD different_JJ genotypes_NNS per_IN patient_NN ._SENT The_DT distribution_NN of_IN the_DT number_NN of_IN different_JJ genotypes_NNS per_IN patient_NN is_VBZ shown_VBN in_IN Fig._NN ._SENT Of_IN the_DT 638_CD genotypes_NNS detected_VBD ,_, 261_CD (_( 40.9_CD %_NN )_) were_VBD low-risk_JJ genotypes_NNS ._SENT A_DT total_NN of_IN 29_CD (_( 14.3_CD %_NN )_) patients_NNS carried_VBD only_RB low-risk_JJ genotypes_NNS and_CC 43_CD (_( 21.2_CD %_NN )_) carried_VBD only_RB high-risk_JJ genotypes_NNS ,_, whereas_IN 130_CD (_( 64.3_CD %_NN )_) patients_NNS carried_VBD both_DT high-_NN and_CC low-risk_JJ types_NNS ._SENT Cervical_JJ scrapes_NNS could_MD be_VB cytologically_RB classified_VBN for_IN 199_CD patients_NNS and_CC revealed_VBD that_DT 22_CD (_( 10.5_CD %_NN )_) patients_NNS showed_VBD normal_JJ (_( Pap_NN I_CD )_) cytology_NN ,_, whereas_IN 149_CD (_( 71.6_CD %_NN )_) patients_NNS showed_VBD inflammation_NN (_( Pap_NP II_NP )_) ._SENT Twenty-eight_JJ patients_NNS (_( 13.4_CD %_NN )_) presented_VBD abnormal_JJ (_( Pap_NP III_NP )_) smears_NNS on_IN cytology_NN ,_, and_CC all_DT of_IN these_DT were_VBD histologically_RB confirmed_VBN to_TO have_VB a_DT low-grade_NN (_( CIN_NP II_NP )_) or/and_NN a_DT high-grade_JJ (_( CIN_NP III_NP )_) squamous_JJ intraepithelial_JJ lesion_NN ._SENT One_CD patient_NN classified_VBN as_IN Pap_NP III_NP was_VBD found_VBN to_TO have_VB a_DT carcinoma_NN in_IN situ_NN on_IN the_DT histological_JJ analysis_NN ._SENT The_DT relationship_NN between_IN cytological_JJ classification_NN and_CC the_DT number_NN of_IN HPV_NP genotypes_NNS detected_VBD is_VBZ shown_VBN in_IN Fig._NN ._SENT There_EX was_VBD a_DT clear_JJ trend_NN for_IN a_DT decrease_NN in_IN the_DT number_NN of_IN genotypes_NNS with_IN higher_JJR Pap_NN classification_NN ._SENT The_DT prevalence_NN of_IN multiple_JJ (_( >1_JJ )_) genotypes_NNS was_VBD higher_JJR in_IN patients_NNS with_IN Pap_NN I_PP or_CC Pap_NP II_NP compared_VBD to_TO those_DT with_IN Pap_NP III_NP (_( chi2_JJ test_NN ,_, P_NN =_SYM 0.02_CD )_) ._SENT The_DT presence_NN of_IN low-risk_JJ and_CC high-risk_JJ genotypes_NNS in_IN the_DT different_JJ cytological_JJ classes_NNS is_VBZ shown_VBN in_IN Table_NP ._SENT At_IN least_JJS one_CD high-risk_JJ genotype_NN was_VBD present_JJ in_IN 89_CD %_NN of_IN the_DT Pap_NN I_PP samples_VBZ ,_, in_IN 84_CD %_NN of_IN the_DT Pap_JJ II_NP samples_NNS ,_, and_CC in_IN 82_CD %_NN of_IN the_DT Pap_JJ III_NP samples_NNS ._SENT These_DT differences_NNS were_VBD not_RB statistically_RB significant_JJ (_( chi2_NN >_SYM 0.05_CD )_) ._SENT Among_IN the_DT 28_CD patients_NNS with_IN squamous_JJ intraepithelial_JJ lesions_NNS ,_, 5_CD (_( 18_CD %_NN )_) carried_VBD exclusively_RB low-risk_JJ genotypes_NNS (_( types_NNS 6_CD ,_, 6_CD ,_, 6_CD and_CC 70_CD ,_, 70_CD ,_, and_CC 44_CD and_CC 74_CD ,_, respectively_RB )_) ,_, 13_CD (_( 46_CD %_NN )_) carried_VBD both_DT low-risk_JJ and_CC high-risk_JJ types_NNS ,_, and_CC 10_CD (_( 36_CD %_NN )_) carried_VBD exclusively_RB high-risk_JJ types_NNS ._SENT The_DT HIV_NP viral_JJ load_NN and_CC the_DT CD4_NP counts_NNS were_VBD determined_VBN for_IN all_DT patients_NNS ._SENT Since_IN virtually_RB all_DT patients_NNS were_VBD found_VBN to_TO be_VB HPV_NP DNA_NP positive_NN ,_, no_DT relation_NN between_IN the_DT CD4_NP count_NN and_CC the_DT presence_NN of_IN HPV_NP could_MD be_VB established_VBN ._SENT Also_RB ,_, there_EX was_VBD no_DT significant_JJ correlation_NN between_IN the_DT number_NN of_IN HPV_NP genotypes_NNS and_CC the_DT CD4_NP count_NN or_CC the_DT HIV_NP viral_JJ load_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Distribution_NN of_IN HPV_NP genotypes_NNS (_( total_NN ,_, 638_LS )_) detected_VBN by_IN SPF10_NP and_CC LiPA_NP in_IN 202_CD HPV-positive_JJ patients_NNS ._SENT Distribution_NN of_IN HPV_NP genotypes_NNS (_( total_NN ,_, 638_LS )_) detected_VBN by_IN SPF10_NP and_CC LiPA_NP in_IN 202_CD HPV-positive_JJ patients_NNS ._SENT The_DT percentage_NN indicates_VBZ the_DT proportion_NN of_IN the_DT patients_NNS in_IN which_WDT a_DT particular_JJ genotype_NN was_VBD observed_VBN ._SENT FIG._NN 2_CD ._SENT |_SYM Frequencies_NNS of_IN the_DT number_NN of_IN HPV_NP genotypes_NNS observed_VBD in_IN the_DT patient_JJ group_NN ._SENT Frequencies_NNS of_IN the_DT number_NN of_IN HPV_NP genotypes_NNS observed_VBD in_IN the_DT patient_JJ group_NN ._SENT FIG._NN 3_CD ._SENT |_SYM Number_NP of_IN HPV_NP genotypes_NNS detected_VBD per_IN cytology_NN class_NN (_( Pap_VB I_PP to_TO III_NP )_) ._SENT Number_NN of_IN HPV_NP genotypes_NNS detected_VBD per_IN cytology_NN class_NN (_( Pap_VB I_PP to_TO III_NP )_) ._SENT Black_JJ bars_NNS indicate_VBP the_DT presence_NN of_IN one_CD genotype_NN ,_, white_JJ bars_NNS indicate_VBP the_DT presence_NN of_IN two_CD genotypes_NNS ,_, vertically_RB striped_VBN bars_NNS indicate_VBP the_DT presence_NN of_IN three_CD genotypes_NNS ,_, and_CC horizontally_RB striped_JJ bars_NNS indicate_VBP the_DT presence_NN of_IN more_JJR than_IN three_CD genotypes_NNS ._SENT The_DT prevalence_NN of_IN multiple_JJ genotypes_NNS was_VBD higher_JJR in_IN patients_NNS with_IN Pap_NN I_PP or_CC Pap_NP II_NP than_IN in_IN those_DT with_IN Pap_NP III_NP ._SENT This_DT difference_NN was_VBD statistically_RB significant_JJ (_( chi2_JJ test_NN ,_, P_NN =_SYM 0.02_CD )_) ._SENT TABLE_NN 1_CD |_SYM Distribution_NN of_IN high-risk_JJ and_CC low-risk_JJ HPV_NP genotypes_NNS in_IN the_DT different_JJ cytology_NN classes_NNS TABLE_NP 2_CD |_SYM Relationship_NN between_IN the_DT number_NN of_IN HPV_NP genotypes_NNS ,_, cytological_JJ classification_NN ,_, and_CC CD4_NP count_NN and_CC HIV_NP viral_JJ load_NN In_IN the_DT present_JJ study_NN ,_, we_PP observed_VBD a_DT very_RB high_JJ prevalence_NN (_( 98_CD %_NN )_) of_IN HPV_NP DNA_NP among_IN HIV-infected_JJ women_NNS ._SENT This_DT prevalence_NN is_VBZ higher_JJR than_IN found_VBN in_IN earlier_JJR studies_NNS ._SENT Palefsky_NP et_FW al._FW observed_VBD an_DT overall_JJ prevalence_NN of_IN HPV_NP DNA_NP of_IN 63_CD %_NN with_IN the_DT My09/11_NP PCR_NP primers_NNS in_IN HIV-infected_JJ women_NNS in_IN the_DT United_NP States_NPS ._SENT Ellerbrock_NP et_FW al._FW observed_VBD a_DT prevalence_NN of_IN HPV_NP DNA_NP of_IN 54_CD %_NN in_IN a_DT cohort_NN of_IN 264_CD HIV-infected_JJ U.S._NP women_NNS ._SENT Goncalves_NP et_FW al._FW studied_JJ Brazilian_JJ HIV-positive_JJ patients_NNS and_CC found_VBD 80.8_CD %_NN of_IN them_PP to_TO be_VB HPV_NP positive_NN ,_, and_CC 45_CD %_NN of_IN these_DT carried_VBN multiple_JJ HPV_NP genotypes_NNS ._SENT The_DT high_JJ prevalence_NN of_IN HPV_NP DNA_NP of_IN 98_CD %_NN in_IN the_DT present_JJ study_NN may_MD be_VB explained_VBN by_IN the_DT very_RB high_JJ sensitivity_NN of_IN the_DT SPF10_NP PCR_NP primer_NN set_VBD ._SENT It_PP is_VBZ likely_JJ that_IN this_DT high_JJ sensitivity_NN permits_VBZ detection_NN of_IN HPV_NP DNA_NP in_IN samples_NNS with_IN a_DT low_JJ HPV_NP viral_JJ load_NN ,_, which_WDT would_MD probably_RB be_VB scored_VBN as_IN HPV_NP negative_JJ with_IN alternative_JJ primer_NN sets_NNS ._SENT The_DT methods_NNS used_VBN in_IN the_DT present_JJ study_NN have_VBP been_VBN extensively_RB validated_VBN ._SENT The_DT sensitivity_NN of_IN the_DT SPF10_NP primer_NN set_NN is_VBZ high_JJ ,_, presumably_RB also_RB due_JJ to_TO the_DT small_JJ size_NN of_IN the_DT amplimer_NN ,_, as_RB was_VBD shown_VBN in_IN earlier_JJR studies_NNS with_IN various_JJ clinical_JJ materials_NNS ._SENT Furthermore_RB ,_, the_DT LiPA_NP method_NN used_VBN for_IN identification_NN of_IN HPV_NP genotypes_NNS has_VBZ been_VBN validated_VBN in_IN different_JJ patient_JJ groups_NNS ._SENT The_DT LiPA_NP was_VBD shown_VBN to_TO be_VB highly_RB reproducible_JJ and_CC accurate_JJ when_WRB used_VBN with_IN different_JJ clinical_JJ samples_NNS from_IN the_DT same_JJ patient_NN or_CC during_IN follow-up_NN studies_NNS ._SENT Furthermore_RB ,_, direct_JJ comparison_NN between_IN the_DT HPV-LiPA_NP and_CC an_DT alternative_JJ reverse_JJ hybridization_NN assay_NN showed_VBD a_DT very_RB high_JJ level_NN of_IN agreement_NN ,_, including_VBG cases_NNS carrying_VBG multiple_JJ HPV_NP genotypes_NNS ._SENT In_IN the_DT present_JJ study_NN ,_, all_DT negative_JJ and_CC positive_JJ controls_NNS yielded_VBD the_DT appropriate_JJ results_NNS ._SENT Taken_VBN together_RB ,_, it_PP is_VBZ unlikely_JJ that_IN the_DT results_NNS of_IN the_DT present_JJ study_NN are_VBP due_JJ to_TO lack_NN of_IN reliability_NN of_IN the_DT methods_NNS used_VBD ._SENT There_EX are_VBP no_DT indications_NNS that_IN the_DT selection_NN of_IN patients_NNS in_IN the_DT present_JJ study_NN was_VBD different_JJ from_IN that_DT in_IN the_DT studies_NNS cited_VBD ._SENT All_DT 204_CD HPV_NP DNA-positive_NP patients_NNS were_VBD further_RBR analyzed_VBN by_IN HPV_NP genotyping_NN ,_, revealing_VBG a_DT particular_JJ distribution_NN of_IN HPV_NP genotypes_NNS ._SENT Low-risk_JJ HPV_NP types_NNS (_( mainly_RB HPV_NP 6_CD ,_, 11_CD ,_, 44_CD ,_, and_CC 53_CD )_) were_VBD also_RB frequently_RB detected_VBN ._SENT Remarkably_RB ,_, genotypes_NNS 6_CD and_CC 51_CD were_VBD more_RBR prevalent_JJ than_IN HPV_NP 16_CD and_CC 18_CD ._SENT In_IN contrast_NN ,_, Goncalves_NP et_FW al._FW reported_VBD that_IN types_NNS 16_CD and_CC 18_CD were_VBD the_DT most_RBS prevalent_JJ types_NNS and_CC also_RB found_VBD that_IN almost_RB 20_CD %_NN of_IN the_DT HPV_NP were_VBD untypeable_JJ ._SENT This_DT may_MD be_VB due_JJ to_TO the_DT restriction_NN fragment_NN length_NN polymorphism-based_JJ genotyping_NN method_NN used_VBD ._SENT Palefsky_NP et_FW al._FW reported_VBD that_IN HPV_NP 53_CD ,_, 58_CD ,_, and_CC 61_CD were_VBD the_DT most_RBS prevalent_JJ types_NNS in_IN a_DT large_JJ HIV-infected_JJ U.S._NP population_NN and_CC that_IN the_DT distribution_NN of_IN HPV_NP types_NNS in_IN HIV-infected_JJ women_NNS may_MD be_VB different_JJ than_IN in_IN HIV-negative_JJ women_NNS from_IN the_DT same_JJ population_NN ._SENT The_DT behavioral_JJ and_CC socioeconomic_JJ characteristics_NNS of_IN HIV-infected_JJ women_NNS may_MD differ_VB from_IN those_DT of_IN women_NNS in_IN the_DT normal_JJ population_NN ._SENT Also_RB ,_, there_EX may_MD be_VB considerable_JJ differences_NNS in_IN the_DT spectrum_NN and_CC prevalence_NN of_IN HPV_NP genotypes_NNS in_IN HIV-infected_JJ women_NNS from_IN different_JJ geographic_JJ origins_NNS ._SENT The_DT majority_NN of_IN patients_NNS in_IN the_DT present_JJ study_NN carried_VBD multiple_JJ genotypes_NNS (_( average_JJ ,_, 3.1_CD types_NNS per_IN patient_NN ;_: range_NN ,_, 1_CD to_TO 10_CD genotypes_NNS )_) ._SENT This_DT may_MD reflect_VB the_DT frequent_JJ exposure_NN of_IN these_DT patients_NNS to_TO multiple_JJ HPV_NP genotypes_NNS due_JJ to_TO unprotected_JJ sexual_JJ contacts_NNS ._SENT In_IN the_DT United_NP States_NPS ,_, Palefsky_NP et_FW al._FW detected_VBN multiple_JJ genotypes_NNS in_IN 36_CD %_NN of_IN the_DT HIV-infected_JJ and_CC 12_CD %_NN of_IN the_DT HIV-negative_JJ individuals_NNS ._SENT Similarly_RB ,_, Ellerbrock_NP et_FW al._FW observed_JJ multiple_JJ infections_NNS in_IN 12_CD %_NN of_IN HIV-infected_JJ women_NNS ._SENT In_IN a_DT Brazilian_JJ population_NN studied_VBN by_IN Goncalves_NP et_FW al._FW ,_, multiple_JJ genotypes_NNS were_VBD found_VBN in_IN 45_CD %_NN of_IN the_DT HPV-positive_JJ patients_NNS ._SENT Again_RB ,_, these_DT differences_NNS may_MD be_VB due_JJ to_TO the_DT genotyping_JJ method_NN employed_VBN ._SENT Another_DT possible_JJ explanation_NN for_IN the_DT high_JJ prevalence_NN of_IN HPV_NP infection_NN could_MD be_VB that_DT failure_NN of_IN the_DT immune_JJ system_NN to_TO clear_VB the_DT infection_NN increases_VBZ the_DT persistence_NN rate_NN of_IN HPV_NP ._SENT Also_RB ,_, HPV_NP replication_NN may_MD be_VB more_RBR efficient_JJ in_IN an_DT immunodeficient_JJ host_NN ,_, which_WDT could_MD result_VB in_IN an_DT increased_VBN detection_NN rate_NN as_RB well_RB as_IN a_DT higher_JJR chance_NN of_IN developing_VBG persistent_JJ HPV_NP infection_NN ._SENT This_DT hypothesis_NN is_VBZ in_IN agreement_NN with_IN findings_NNS in_IN a_DT recent_JJ longitudinal_JJ study_NN showing_VBG that_DT HPV_NP clearance_NN was_VBD strongly_RB reduced_VBN in_IN HIV-infected_JJ women_NNS ._SENT If_IN exposure_NN to_TO novel_NN infection_NN continues_VBZ ,_, this_DT may_MD result_VB in_IN accumulation_NN of_IN different_JJ HPV_NP genotypes_NNS and_CC a_DT higher_JJR prevalence_NN of_IN women_NNS infected_VBN with_IN multiple_JJ HPV_NP genotypes_NNS ._SENT If_IN the_DT frequency_NN of_IN multiple_JJ HPV_NP genotypes_NNS is_VBZ related_VBN to_TO the_DT degree_NN of_IN immunocompetence_NN of_IN the_DT host_NN ,_, one_PP could_MD speculate_VB that_IN the_DT number_NN of_IN HPV_NP genotypes_NNS would_MD be_VB associated_VBN with_IN CD4_NP counts_NNS and_CC HIV_NP viral_JJ load_NN ._SENT However_RB ,_, the_DT present_JJ study_NN did_VBD not_RB support_VB this_DT hypothesis_NN ,_, since_IN there_EX was_VBD no_DT significant_JJ association_NN between_IN CD4_NP cell_NN counts_NNS and_CC the_DT number_NN of_IN HPV_NP genotypes_NNS ._SENT Our_PP$ findings_NNS are_VBP different_JJ from_IN the_DT data_NNS obtained_VBN by_IN Palefsky_NP et_FW al._FW ,_, who_WP found_VBD the_DT highest_JJS number_NN of_IN HPV_NP DNA-positive_NP subjects_NNS and_CC the_DT highest_JJS frequency_NN of_IN multiple_JJ infections_NNS among_IN patients_NNS with_IN a_DT CD4_NP count_NN of_IN <200/mm3_NN ._SENT This_DT difference_NN may_MD be_VB due_JJ to_TO the_DT very_RB high_JJ sensitivity_NN of_IN the_DT detection_NN and_CC genotyping_NN method_NN used_VBN in_IN the_DT present_JJ study_NN ._SENT Also_RB ,_, most_RBS HIV-infected_JJ Brazilian_JJ patients_NNS do_VBP receive_VB some_DT form_NN of_IN antiviral_JJ treatment_NN ,_, which_WDT may_MD result_VB in_IN higher_JJR CD4_NP counts_NNS (_( as_RB long_RB as_IN no_DT resistance_NN appears_VBZ )_) but_CC may_MD not_RB yield_VB an_DT immediate_JJ improvement_NN in_IN the_DT ability_NN of_IN the_DT immune_JJ system_NN to_TO clear_VB HPV_NP infections_NNS or_CC reduce_VB the_DT viral_JJ load_NN ._SENT Of_IN the_DT cases_NNS without_IN cytological_JJ abnormalities_NNS ,_, the_DT majority_NN (_( 71.6_CD %_NN )_) had_VBD inflammation_NN (_( Pap_NP II_NP )_) ._SENT This_DT is_VBZ in_IN agreement_NN with_IN earlier_JJR observations_NNS in_IN Brazilian_JJ HIV-infected_JJ patients_NNS ,_, where_WRB 75.9_CD %_NN of_IN the_DT samples_NNS showed_VBD inflammation_NN ._SENT The_DT number_NN of_IN HPV_NP genotypes_NNS appears_VBZ to_TO be_VB lower_JJR in_IN patients_NNS with_IN Pap_JJ III_NP cytology_NN ._SENT The_DT majority_NN of_IN patients_NNS with_IN squamous_JJ intraepithelial_JJ lesions_NNS in_IN this_DT population_NN harbored_VBD one_CD or_CC two_CD HPV_NP types_NNS ,_, whereas_IN only_RB 2_CD %_NN of_IN these_DT patients_NNS were_VBD infected_VBN with_IN more_JJR than_IN three_CD HPV_NP types_NNS ._SENT Conversely_RB ,_, patients_NNS with_IN Pap_NN I_PP or_CC II_NP carried_VBD significantly_RB more_RBR multiple_JJ types_NNS ._SENT These_DT observations_NNS would_MD be_VB consistent_JJ with_IN the_DT hypothesis_NN that_IN the_DT development_NN of_IN cervical_JJ dysplasia_NN has_VBZ a_DT clonal_JJ basis_NN ._SENT In_IN conclusion_NN ,_, a_DT very_RB high_JJ proportion_NN of_IN HIV-infected_JJ women_NNS in_IN this_DT study_NN were_VBD found_VBN positive_JJ for_IN HPV_NP DNA_NP ._SENT In_IN contrast_NN to_TO immunocompetent_JJ women_NNS ,_, infection_NN with_IN multiple_JJ HPV_NP types_NNS is_VBZ present_JJ in_IN the_DT majority_NN of_IN the_DT HIV-infected_JJ patients_NNS ._SENT However_RB ,_, the_DT number_NN of_IN HPV_NP genotypes_NNS was_VBD not_RB associated_VBN with_IN HIV_NP disease_NN markers_NNS such_JJ as_IN HIV_NP plasma_NN viral_JJ load_NN and_CC CD4_JJ cell_NN counts_NNS ._SENT The_DT findings_NNS of_IN the_DT present_JJ study_NN are_VBP currently_RB being_VBG reanalyzed_VBN with_IN another_DT sensitive_JJ HPV_NP DNA_NP detection_NN method_NN ._SENT Preliminary_JJ results_NNS confirmed_VBD both_CC the_DT extremely_RB high_JJ prevalence_NN of_IN HPV_NP and_CC the_DT presence_NN of_IN multiple_JJ genotypes_NNS in_IN many_JJ of_IN these_DT patients_NNS (_( J._NP E._NP Levi_NP ,_, personal_JJ communication_NN )_) ._SENT Investigation_NN of_IN HIV-infected_JJ patients_NNS is_VBZ of_IN particular_JJ value_NN because_IN they_PP show_VBP ,_, as_RB demonstrated_VBN here_RB ,_, a_DT much_RB higher_JJR multiplicity_NN of_IN infection_NN than_IN other_JJ patient_JJ groups_NNS and_CC may_MD manifest_VB the_DT effects_NNS of_IN HPV_NP infection_NN earlier_RBR and_CC more_RBR intensively_RB ._SENT Therefore_RB ,_, sensitive_JJ detection_NN methods_NNS as_RB well_RB as_IN specific_JJ genotyping_NN tools_NNS are_VBP required_VBN and_CC may_MD have_VB important_JJ consequences_NNS for_IN the_DT management_NN of_IN immunocompromised_JJ patients_NNS ._SENT 